Breast cancer stem cell-derived exosomal lnc-PDGFD induces fibroblast-niche formation and promotes lung metastasis
Oncogene · 2025
DOI: 10.1038/s41388-024-03237-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncogene, 2025. Verfasst von Tingting Tang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Institute, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, 221004, Jiangsu, China. Hauptthemen laut MEDLINE: Exosomes, Neoplastic Stem Cells, Lung Neoplasms, RNA, Long Noncoding. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China (National Science Foundation of China), Natural Science Foundation of Jiangsu Province (Jiangsu Provincial Natural Science Foundation).
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC) is the most aggressive subtype with high metastatic potential and lack of therapeutic targets. Breast cancer stem cells (BCSCs) are enriched in TNBC and contribute to its metastatic propensity. Accumulating evidence suggests that cancer-derived exosomes are key drivers of premetastatic niche formation in distal organs. However, the function and underlying mechanism of BCSC-derived exosomes in TNBC metastasis remain elusive. Here, we demonstrated that BCSC-derived exosomes exhibit a greater capacity to activate fibroblasts and promote TNBC cell metastasis to the lung than non-BCSC-derived exosomes. Additionally, we found that upregulation of exosomal long non-coding RNA platelet derived growth factor D (lnc-PDGFD) expression in BCSCs is responsible for fibroblast activation through YBX1/NF-kB signaling in the lung. Activated fibroblasts further promote tumor progression by secreting IL-11. Taken together, BCSC-derived exosomes enriched with lnc-PDGFD could activate fibroblasts, thereby facilitating lung metastasis in TNBC patients. These results provide new insights into the mechanism of TNBC metastasis to the lung.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cancer Institute, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, 221004, Jiangsu, China.
- Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, 99 West Huaihai Road, Xuzhou, 221002, Jiangsu, China.
- Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, 221004, Jiangsu, China.
- Department of Pathology, The Affiliated Hospital of Xuzhou Medical University, 99 West Huaihai Road, Xuzhou, 221002, Jiangsu, China.
- Center of Clinical Oncology, The Affiliated Hospital of Xuzhou Medical University, 99 West Huaihai Road, Xuzhou, 221002, Jiangsu, China. jnzheng@xzhmu.edu.cn.
- Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Xuzhou Medical University, 209 Tongshan Road, Xuzhou, 221004, Jiangsu, China. jnzheng@xzhmu.edu.cn.
Förderung
- National Natural Science Foundation of China (National Science Foundation of China)
- Natural Science Foundation of Jiangsu Province (Jiangsu Provincial Natural Science Foundation)
Zitieren
APA
Tang, T., Yang, T., Xue, H., Liu, X., Yu, J., Liang, C., Li, D., Xiang, C., Zheng, J., Wei, L., & Ma, B. (2025). Breast cancer stem cell-derived exosomal lnc-PDGFD induces fibroblast-niche formation and promotes lung metastasis. Oncogene. https://doi.org/10.1038/s41388-024-03237-4
Vancouver
Tang T, Yang T, Xue H, Liu X, Yu J, Liang C, et al. Breast cancer stem cell-derived exosomal lnc-PDGFD induces fibroblast-niche formation and promotes lung metastasis. Oncogene. 2025. doi:10.1038/s41388-024-03237-4
BibTeX
@article{Tang2025,
author = {Tang, Tingting and Yang, Tao and Xue, Huijie and Liu, Xiao and Yu, Jie and Liang, Chen and Li, Dameng and Xiang, Chenxi and Zheng, Junnian and Wei, Liang and Ma, Bo},
title = {Breast cancer stem cell-derived exosomal lnc-PDGFD induces fibroblast-niche formation and promotes lung metastasis},
journal = {Oncogene},
year = {2025},
doi = {10.1038/s41388-024-03237-4}
}
EUVIMED